Stockscreener 앱 받기
28.09
4.85%
1.30
시간 외 거래:
28.00
-0.09
-0.32%
전일 마감가:
$26.79
열려 있는:
$28.75
하루 거래량:
1.56M
Relative Volume:
4.04
시가총액:
$851.97M
수익:
$339.92M
순이익/손실:
$-12.83M
주가수익비율:
-65.40
EPS:
-0.4295
순현금흐름:
$4.52M
1주 성능:
+13.79%
1개월 성능:
+17.78%
6개월 성능:
-28.69%
1년 성능:
+85.41%
1일 변동 폭
$27.50
$30.81
1주일 범위
$23.73
$30.81
52주 변동 폭
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
명칭
Castle Biosciences Inc
전화
866-788-9007
주소
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, IQV, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
28.09 | 741.26M | 339.92M | -12.83M | 4.52M | -0.4295 |
TMO
Thermo Fisher Scientific Inc
|
574.38 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
195.02 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.07 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
IQV
Iqvia Holdings Inc
|
235.07 | 35.59B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
138.37 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-04-30 | 개시 | Lake Street | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | 재확인 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | BTIG Research | Buy |
| 2019-08-19 | 개시 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | Robert W. Baird | Outperform |
| 2019-08-19 | 개시 | SVB Leerink | Outperform |
모두보기
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
Castle Biosciences Inc (CSTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Castle Biosciences Inc (CSTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Castle Biosciences Inc (CSTL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Castle Biosciences Inc (CSTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Castle Biosciences Inc (CSTL) Cash Flow - TradingKey
Earnings Preview: CSTL to Report Financial Results Post-market on July 30 - Moomoo
Castle Biosciences Inc (CSTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Castle Biosciences, Inc. (CSTL) Investor Outlook: Exploring A 67.89% Potential Upside - DirectorsTalk Interviews
CSTL|Castle Biosciences Inc|Price:25.093|Chg%:-0.387 - TradingKey
Castle Biosciences sets live webcast for Aug. 12 conference - Stock Titan
New York State Department of Health Approves Castle’s AdvanceAD-Tx Test - The Dermatology Digest
The Technical Signals Behind (CSTL) That Institutions Follow - Stock Traders Daily
Castle Biosciences CEO Maetzold sells $95,622 in company stock - Investing.com UK
Form 4 Castle Biosciences Inc For: 16 July By Investing.com - Investing.com Nigeria
Castle Biosciences CEO Maetzold sells $95,622 in company stock By Investing.com - Investing.com UK
Castle Biosciences (CSTL) CEO sells 4,172 shares via family trusts - Stock Titan
Castle Biosciences CEO Derek J. Maetzold disposes of 550 common shares worth $12,606 - Bitget
Castle Biosciences Gets New York State Department of Health Approval of AdvanceAD-Tx Test - Moomoo
Castle Biosciences receives New York approval for atopic dermatitis test By Investing.com - Investing.com Nigeria
Castle Biosciences receives New York approval for atopic dermatitis test - Investing.com
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test - norfolkneradio.com
CSTL Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Uncertain Revenue Outlook - DonanımHaber
Castle Biosciences Inc (CSTL) Stock Down 3.4% -- Now Undervalued? GF Score: 77/100 - GuruFocus
CSTL Q1 2026 Earnings: Slight EPS Beat Amid Operational ProgressRevenue Guidance Update - DonanımHaber
July 30 set for Castle Biosciences Q2 2026 earnings webcast - Traders Union
Castle Biosciences (CSTL) to Release Q2 Financial Results on Jul - GuruFocus
Castle Biosciences sets July 30 webcast for Q2 results - Stock Titan
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 - Yahoo Finance
Castle Biosciences updates its melanoma testing strategy as diagnostics demand grows - Ad-hoc-news.de
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus - AOL.com
Castle Biosciences (CSTL) COO sells 8,586 shares under 10b5-1 plan - Stock Titan
Form 4 Castle Biosciences Inc For: 6 July By Investing.com - Investing.com Nigeria
Derek Maetzold, pres. & CEO, sells $238,916 of Castle Biosciences stock - Investing.com India
Castle Biosciences (CSTL) CEO sells 9,836 shares via 10b5-1 plan - Stock Titan
Q1 2026 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Enterprise value to revenue forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Castle Biosciences Inc (CSTL) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Form 144 Castle Biosciences For: 1 July By Investing.com - Investing.com Canada
Maetzold family Rule 144 sales reported for CSTL (CSTL) — multiple small lots - Stock Titan
Castle Biosciences (CSTL) Surges 6% as Bullish Momentum BuildsDynamic Hedging - dars.gov.et
Castle Biosciences updates its melanoma test data, shares in biotech focus - AD HOC NEWS
Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down - Yahoo Finance
Castle Biosciences (CSTL) Study Highlights Advancements in Melan - GuruFocus
Castle Biosciences, Inc. Actuals & Estimates (NASDAQ:CSTL) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool By Investing.com - Investing.com South Africa
Castle Biosciences, Inc. Actuals & Estimates (TRADEGATE:086) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool - Investing.com
Enterprise value to EBIT forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy - norfolkneradio.com
Roth Capital Initiates Castle Biosciences at Buy - Moomoo
Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones - Stock Traders Daily
Castle Biosciences Inc (CSTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Castle Biosciences Inc 주식 (CSTL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jul 14 '26 |
Sale |
22.92 |
3,622 |
83,016 |
12,090 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jul 14 '26 |
Sale |
22.92 |
550 |
12,606 |
21,479 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jul 01 '26 |
Option Exercise |
2.39 |
6,214 |
14,851 |
27,693 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jul 01 '26 |
Sale |
24.29 |
6,214 |
150,938 |
21,479 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jul 01 '26 |
Sale |
24.29 |
3,622 |
87,978 |
12,368 |
| Oelschlager Kristen M | Chief Operating Officer |
Jul 01 '26 |
Sale |
24.42 |
8,586 |
209,650 |
21,874 |
0.55%
2.63%
자본화:
|
볼륨(24시간):